← Back to Search

Hormone Therapy

Tamoxifen for Pancreatic Cysts (MCN_Tam Trial)

Phase 1
Waitlist Available
Led By Kelsey Klute, MD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months (approximately 360 days)
Awards & highlights
No Placebo-Only Group

Summary

"This trial will test if tamoxifen can prevent the growth of precancerous cells in the pancreas in patients who are not having immediate surgery. About 15 patients will take tamoxifen daily

Who is the study for?
This trial is for individuals with certain types of non-cancerous pancreatic cysts known as mucinous cystic neoplasms (MCNs) who are not scheduled for immediate surgery to remove these cysts. Specific eligibility details are not provided.
What is being tested?
The study is testing the effectiveness of a medication called Tamoxifen, taken orally at a dose of 20mg daily, in preventing cancer in patients with MCN. Up to 15 participants will be involved and the treatment duration is up to 24 weeks.
What are the potential side effects?
While specific side effects for this trial aren't listed, common side effects of Tamoxifen can include hot flashes, vaginal discharge or bleeding, mood swings, fatigue, and an increased risk of blood clots.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months (approximately 360 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months (approximately 360 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility, by adherence rate
Feasibility, by retention rate
Secondary study objectives
Objective response rate (ORR) of pancreatic MCN

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TamoxifenExperimental Treatment1 Intervention
Tamoxifen 20mg by mouth daily for up to 6 months

Find a Location

Who is running the clinical trial?

University of NebraskaLead Sponsor
555 Previous Clinical Trials
1,145,370 Total Patients Enrolled
Kelsey Klute, MDPrincipal InvestigatorUniversity of Nebraska
~10 spots leftby Nov 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top